CHELSEA KIGERL: Open Payments
NPI 1326774993 · FONTANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,210 in 57 payments from 13 companies in 2025. Trend: 2023 $909 · 2024 $1,880 · 2025 $2,210
Food & beverage: $2,129Education: $81
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 6 | $367 |
| ABBVIE INC. | 10 | $351 |
| GENZYME CORPORATION | 10 | $331 |
| Galderma Laboratories, L.P. | 2 | $290 |
| LEO Pharma Inc. | 5 | $210 |
| Novartis Pharmaceuticals Corporation | 4 | $194 |
| Arcutis Biotherapeutics, Inc. | 8 | $173 |
| UCB, Inc. | 3 | $89 |
| Janssen Biotech, Inc. | 2 | $77 |
| Amgen Inc. | 3 | $52 |
Products named: DUPIXENT, SKYRIZI, NEMLUVIO, ADBRY, Zoryve, Bimzelx, COSENTYX, TREMFYA.
Industry payments across CA — which companies pay providers there.
